

## Mainstay Medical Announces Date for 2014 Half Year Results

**Dublin – Ireland, 22<sup>nd</sup> August 2014** – Mainstay Medical International plc (*Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE*) announces that it will release 2014 Half Year Results on Thursday, August 28<sup>th</sup>, 2014 at 7:00am Dublin time (8:00am Paris; 2:00am New York).

The Company will host a live conference call (in English) for analysts and investors on Thursday, August 28<sup>th</sup>, 2014 at 2:30pm Dublin-London time (3:30pm Paris; 09:30am New York).

Dial-in details for this call are outlined below:

Ireland Toll Free Number:	1800 936 842
France Toll Free Number:	0805 101 988
Finland Toll Free Number:	0800 523 133
Netherlands Toll Free Number:	0800 265 8619
USA Toll Free Number:	1866 928 7517
International Non Toll Free Number:	+44 203 139 4830
<b>Passcode:</b>	<b>56311508#</b>

During the conference call there will be an opportunity to ask questions. Instructions for this will be provided at the start of the call. Questions for the conference call are welcomed in advance via e-mail to [investor-relations@mainstay-medical.com](mailto:investor-relations@mainstay-medical.com).

- End -

### About Mainstay

Mainstay is a medical device company which is developing an innovative implantable neurostimulation medical device, ReActiv8, for people with debilitating Chronic Low Back Pain (CLBP). Low Back Pain is the leading cause of activity limitation and work absence throughout much of the developed world, imposing a high economic burden on individuals, families, communities, industry, and governments.

The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States and Australia, and is listed on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

### About Chronic Low Back Pain

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that stabilize the spine in the lower back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve spine stability, allowing the body to recover from CLBP.

People with debilitating CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spinal surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on economies.

Further information can be found at [www.mainstay-medical.com](http://www.mainstay-medical.com)

**Media queries to:**

Jonathan Neilan, FTI Consulting  
Tel: +353 1 663 3686  
Email: [jonathan.neilan@fticonsulting.com](mailto:jonathan.neilan@fticonsulting.com)

Paul McSharry, FTI Consulting  
Tel: +353 1 663 3609 / +353 87 240 6642  
Email: [paul.mcsharry@fticonsutling.com](mailto:paul.mcsharry@fticonsutling.com)

Jeanne Bariller, FTI Consulting  
Tel: +33 1 47 03 6863 / +33 67 412 4452  
Email: [jeanne.bariller@fticonsulting.com](mailto:jeanne.bariller@fticonsulting.com)

**ESM Advisers:**

Fergal Meegan / Barry Murphy, Davy  
Tel: +353 1 6796363  
Email: [fergal.meegan@davy.ie](mailto:fergal.meegan@davy.ie) / [barry.murphy2@davy.ie](mailto:barry.murphy2@davy.ie)

**Forward looking statements**

This announcement includes statements that are, or may be deemed to be, forward looking statements. These forward looking statements can be identified by the use of forward looking terminology, including the terms “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “should” or “will”, or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward looking statements include all matters that are not historical facts. They appear throughout this announcement and include, but are not limited to, statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s results of operations, financial position, prospects, financing strategies, expectations for product design and development, regulatory approvals, reimbursement arrangements, costs of sales and market penetration.

By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward looking statements are not guarantees of future performance and the actual results of the Company’s operations, and the development of the markets and the industry in which the Company operates, may differ materially from those described in, or suggested by, the forward looking statements contained in this announcement. In addition, even if the Company’s results of operations, financial position and growth, and the development of the markets and the industry in which the Company operates, are consistent with the forward looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments of the Company to differ materially from those expressed or implied by the forward looking statements including, without limitation, general economic and business conditions, the global medical device market conditions, industry trends, competition, changes in law or regulation, changes in taxation regimes, the availability and cost of capital, currency fluctuations, changes in its business strategy, political and economic uncertainty. The forward-looking statements herein speak only at the date of this announcement.